Chalfin Heather J, Liu Jen-Jane, Gandhi Nilay, Feng Zhaoyong, Johnson Daniel, Netto George J, Drake Charles G, Hahn Noah M, Schoenberg Mark P, Trock Bruce J, Scott Andrew V, Frank Steven M, Bivalacqua Trinity J
James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ann Surg Oncol. 2016 Aug;23(8):2715-22. doi: 10.1245/s10434-016-5193-4. Epub 2016 Mar 24.
Perioperative blood transfusion (PBT) has been inconsistently associated with adverse outcomes. Bladder cancer patients are unique as they frequently undergo neoadjuvant chemotherapy (NAC) with resulting immunosuppression, which may be exacerbated by transfusion-related immunomodulation. We examined the effect of leukoreduced PBT on oncologic outcomes and perioperative morbidity in radical cystectomy (RC) patients who received NAC, quantifying exposure with a novel dose-index variable.
The Johns Hopkins Radical Cystectomy database was queried for patients who had undergone NAC followed by RC from 2010 to 2013. Overall, 119 patients had available PBT and survival data. A multivariable Cox model evaluated risk factors, including pathologic stage, Charlson Comorbidity Index, age, race, year of surgery, surgical margin status, PBT, and preoperative hemoglobin for bladder cancer-specific survival (CSS) and overall survival (OS). Logistic regression models determined factors that were independently associated with perioperative morbidity.
Median follow-up was 7.8 months (range 0.2-41.8), and during follow-up there were 25 deaths and 21 cancer deaths. PBT significantly predicted OS (hazard ratio [HR] 1.26, 95 % confidence interval [CI] 1.07-1.49; p = 0.005), CSS (HR 1.32, 95 % CI 1.11-1.57; p = 0.002), and morbidity (odds ratio [OR] 1.67, 95 % CI 1.26-2.21; p = 0.004) in univariate analyses. In multivariable models, PBT was significantly associated with morbidity (OR 1.77, 95 % CI 1.30-2.39; p = 0.0002), but not OS or CSS. Intraoperative transfusion was associated with decreased OS and CSS, and increased morbidity, whereas postoperative transfusion was only associated with increased morbidity.
Intraoperative blood transfusion was associated with increased perioperative morbidity and worsened OS and CSS in patients undergoing RC who had NAC. Although PBT may be life-saving in certain patients, a restrictive transfusion strategy may improve outcomes.
围手术期输血(PBT)与不良预后的关联并不一致。膀胱癌患者较为特殊,因为他们经常接受新辅助化疗(NAC),从而导致免疫抑制,而输血相关的免疫调节可能会加剧这种情况。我们研究了白细胞滤除的PBT对接受NAC的根治性膀胱切除术(RC)患者肿瘤学结局和围手术期发病率的影响,并使用一种新的剂量指数变量来量化暴露情况。
查询约翰霍普金斯根治性膀胱切除术数据库,以获取2010年至2013年期间接受NAC后行RC的患者。总体而言,119例患者有可用的PBT和生存数据。多变量Cox模型评估了风险因素,包括病理分期、Charlson合并症指数、年龄、种族、手术年份、手术切缘状态、PBT和术前血红蛋白,以分析膀胱癌特异性生存(CSS)和总生存(OS)情况。逻辑回归模型确定了与围手术期发病率独立相关的因素。
中位随访时间为7.8个月(范围0.2 - 41.8个月),随访期间有25例死亡和21例癌症死亡。在单变量分析中,PBT显著预测了OS(风险比[HR] 1.26,95%置信区间[CI] 1.07 - 1.49;p = 0.005)、CSS(HR 1.32,95% CI 1.11 - 1.57;p = 0.002)和发病率(比值比[OR] 1.67,95% CI 1.26 - 2.21;p = 0.004)。在多变量模型中,PBT与发病率显著相关(OR 1.77,95% CI 1.30 - 2.39;p = 0.0002),但与OS或CSS无关。术中输血与OS和CSS降低以及发病率增加相关,而术后输血仅与发病率增加相关。
在接受NAC的RC患者中,术中输血与围手术期发病率增加以及OS和CSS恶化相关。虽然PBT在某些患者中可能挽救生命,但限制性输血策略可能会改善结局。